Abstract
Fibrinogen, D-dimer, NT-proBNP, and Lp(a) provide valuable prognostic information for major adverse cardiovascular events (MACE) when applied to patients with acute coronary syndrome (ACS) who lack standard modifiable cardiovascular risk factors (SMuRFs). A multimarker strategy, combining these biomarkers to reflect different pathophysiological processes alongside traditional clinical factors, significantly improves cardiovascular risk stratification in this challenging population.
Introduction
Most patients who suffer from Acute Coronary Syndrome (ACS) present with at least one of the "big four" standard modifiable cardiovascular risk factors (SMuRFs): smoking, diabetes, hypertension, or hypercholesterolemia. However, up to 15% of ACS patients present with none of these. These "SMuRF-less" patients pose a significant clinical challenge; because they lack traditional red flags, they may be perceived as lower risk, yet they often experience higher rates of mortality and recurrent events. This study investigates whether circulating biomarkers can fill this diagnostic gap by providing a clearer picture of the underlying pathophysiological processes—such as inflammation and coagulation—driving their disease.
Methods and Study Population
The researchers conducted a retrospective, observational study at Tianjin Chest Hospital, screening 35,432 consecutive ACS patients treated between January 2014 and December 2017. The cohort was narrowed to 621 patients who lacked all four SMuRFs and had complete follow-up data.
Seven candidate biomarkers were initially evaluated: hs-CRP, Fibrinogen, D-dimer, NT-proBNP, Lp(a), Uric Acid, and GGT. The primary endpoint was MACE, defined as cardiovascular death, myocardial infarction, or stroke, over a median follow-up period of 5 years.
Key Results and Insights
Of the seven markers analyzed, four remained independent predictors of MACE after adjusting for age, gender, and heart function (LVEF): Fibrinogen, D-dimer, NT-proBNP, and Lp(a). Among these, D-dimer showed the strongest association, suggesting that activated coagulation pathways play a dominant role in disease progression for patients lacking traditional metabolic risks.
The risk of a major event increased dramatically with the number of elevated biomarkers. A patient with four elevated markers was six times more likely to experience MACE than a patient with none (Adjusted Hazard Ratio: 6.008).
Predictive Accuracy
Standard clinical metrics like Left Ventricular Ejection Fraction (LVEF) and kidney function (eGFR) provided a baseline C-statistic of only 0.592. Integrating the multimarker score boosted this to 0.711 ($P < 0.001$), representing a substantial leap in predictive accuracy. The Net Reclassification Index (NRI) was 0.549 ($P < 0.001$), indicating that the model correctly moved a large portion of patients into more accurate risk categories.
Discussion and Limitations
This study identifies specific thresholds for risk in SMuRF-less patients: Fibrinogen $\ge$ 3.26 g/L, D-dimer $\ge$ 0.87 ug/ml, NT-proBNP $\ge$ 169 pg/ml, and Lp(a) $\ge$ 77.9 mmol/L. While the multimarker score is statistically significant, the authors note that as a retrospective, single-center study, these findings require validation in larger, multi-ethnic prospective cohorts. Additionally, because biomarkers were only measured once at admission, future research into dynamic changes over time may provide even greater prognostic value. Despite these limitations, the multimarker strategy offers a robust path forward for identifying high-risk individuals who might otherwise be overlooked by traditional risk models.
Summary updated